SCHEMBL7747710

SCHEMBL7747710

CC(=O)N(N)CCC(=O)O

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 0.42
SLC15A2 Q16348 1/20 0.42
PHF8 Q9UPP1 6/20 0.41
KDM2A Q9Y2K7 6/20 0.41
EGLN1 Q9GZT9 3/20 0.41
KDM4E B2RXH2 3/20 0.41
KDM5C P41229 3/20 0.41
KDM6B O15054 1/20 0.41
ALKBH5 Q6P6C2 1/20 0.38
SUCNR1 Q9BXA5 1/20 0.38
KDM7A Q6ZMT4 2/20 0.38
HDAC3 O15379 2/20 0.38
HDAC1 Q13547 2/20 0.38
HDAC2 Q92769 2/20 0.38
HDAC8 Q9BY41 2/20 0.38
FFAR3 O14843 1/20 0.38
ALDH1A1 P00352 1/20 0.36
ALDH2 P05091 1/20 0.36
GABRP O00591 3/20 0.36
GABRD O14764 3/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL8654449 0.98 LMNA (0.40) LMNASLC15A2PHF8KDM2AEGLN1
Water SCHEMBL7773339 0.98 LMNA (0.40) LMNASLC15A2PHF8KDM2AEGLN1
SCHEMBL11685772 0.79 KMT2A (0.54) LMNAKDM4EALDH1A1TSHRKMT2A
SCHEMBL29405740 0.79 LMNA (0.42) LMNAPHF8KDM2AEGLN1KDM4E
SCHEMBL29955022 0.76
SCHEMBL7398732 0.75 LMNA (0.38) LMNAPHF8KDM2AEGLN1KDM4E
SCHEMBL7401740 0.75 MEN1 (0.37) LMNAPHF8KDM2AEGLN1KDM4E
SCHEMBL15787944 0.74
SCHEMBL19520942 0.74
SCHEMBL14566299 0.74 ALDH1A1 (0.48) LMNASLC15A2PHF8KDM2AEGLN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20010051730-A1 Beta-alanine derivative and a process for the preparation thereof FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2001-12-13 US disclosed
EP-1121346-A1 NEW PROCESSES FOR PRODUCING BETA-ALANINE DERIVATIVE FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2001-08-08 EP disclosed
WO-2000021932-A1 NEW PROCESSES FOR PRODUCING β-ALANINE DERIVATIVE FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2000-04-20 WO disclosed
EP-0888302-A1 N- (R)-1- 3-(4-PIPERIDYL)PROPIONYL-3-PIPERIDYLCARBONYL]-2(S)-ACETYLAMINO-BETA-ALANINE AS FIBRINOGEN RECEPTOR ANTAGONIST FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1999-01-07 EP disclosed
EP-0869944-A1 N-ACYLPIPERIDINYLCARBONYLAMINOCARBOXYLIC ACIDS AND THEIR USE AS GLYCOPROTEIN IIB/IIa ANTAGONISTS AND FIBRINOGEN-BLOOD PLATELETS BINDING INHIBITORS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1998-10-14 EP disclosed
WO-1997033869-A1 N-[(R)-1-{3-(4-PIPERIDYL)PROPIONYL-3-PIPERIDYLCARBONYL]-2(S)-ACETYLAMINO-BETA-ALANINE AS FIBRINOGEN RECEPTOR ANTAGONIST FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1997-09-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010051730-A1 Beta-alanine derivative and a process for the preparation thereof F13B, FGB, TGFB1 LMNA 899/4885SLC15A2 1976/4885PHF8 4700/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.